Cue Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
Cue Biopharma, Inc. (CUE)
US:NASDAQ Investor Relations:
cuebiopharma.gcs-web.com/news-releases
Company Research
Source: GlobeNewswire
Advanced research and development of CUE-401 for IND (Investigational New Drug) readiness –CUE-401 is the Company’s lead asset for the treatment of autoimmune and inflammatory diseasesAppointed industry veteran Lucinda Warren as Chief Financial and Business OfficerRaised net proceeds of $10.2M through an underwritten public offeringAnnounced strategic collaboration and license agreement with ImmunoScape to develop breakthrough cell therapy approach for solid tumors – Entitled to receive upfront payments totaling $15M BOSTON, March 16, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune and inflammatory diseases, today reported fourth quarter and full year 2025 financial results. “During the fourth quarter and throughout the full year 2025, the Company successfully met its strategic developme
Show less
Read more
Impact Snapshot
Event Time:
CUE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CUE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CUE alerts
High impacting Cue Biopharma, Inc. news events
Weekly update
A roundup of the hottest topics
CUE
News
- Cue Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights [Yahoo! Finance]Yahoo! Finance
- Cue Biopharma to Present New In vitro Data for CUE-401 at the 20th World Immune Regulation Meeting (WIRM) 2026 [Yahoo! Finance]Yahoo! Finance
- Cue Biopharma to Present New In vitro Data for CUE-401 at the 20th World Immune Regulation Meeting (WIRM) 2026GlobeNewswire
- Cue Biopharma Announces Preclinical Safety and Tolerability Data for CUE-401 for the Treatment of Autoimmune and Inflammatory DiseasesGlobeNewswire
- Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Financial and Business OfficerGlobeNewswire
CUE
Sec Filings
- 3/17/26 - Form S-3
- 3/16/26 - Form ARS
- 3/16/26 - Form 8-K
- CUE's page on the SEC website